A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers

Inclusion Criteria

• •1. Patient with histology-proven malignant solid tumor other than malignant lymphoma
• •2. Patients with age between 18 and 75
• •3. Patients with Karnofsky performance score (KPS) of at least 60
• •4. Patients planned for at least 4 cycles of intensive cytotoxic chemotherapy (either as part of curative therapy or as palliative therapy), except for those receiving single agent cisplatin chemotherapy alone concurrently with radiation for radiosensitization
• •5. Patients with at least 6 months' life expectany from date of recruitment
• •6. Patients with normal liver function tests including alanine aminpotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl-transpeptidase (GGT), and bilirubin
• •7. Patients with no known history of radiological \&/or histological diagnosis of chronic active hepatitis or cirrhosis of any cuase, or history of prior hepatitis B reactivation, or prior chronic therapy for HBV within 6 months
• •8. Patients with no evidence of autoimmune hepatitis, hepatitis C or delta virus infection, HIV infection or radiological evidence of liver metastasis
• •9. Patients with negative pregnancy test for female gender of child-bearing age